193 related articles for article (PubMed ID: 16538115)
1. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
Koutroubakis IE; Karmiris K; Makreas S; Xidakis C; Niniraki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):421-5. PubMed ID: 16538115
[TBL] [Abstract][Full Text] [Related]
2. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
3. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
Gasche C; Waldhoer T; Feichtenschlager T; Male C; Mayer A; Mittermaier C; Petritsch W;
Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anaemia in inflammatory bowel disease with iron sucrose.
Bodemar G; Kechagias S; Almer S; Danielson BG
Scand J Gastroenterol; 2004 May; 39(5):454-8. PubMed ID: 15180183
[TBL] [Abstract][Full Text] [Related]
8. Management of iron deficiency anaemia in gynaecological patients at Jinnah Postgraduate Medical Centre, Karachi.
Nasir A; Yasmin H; Korejo R
J Pak Med Assoc; 2011 Oct; 61(10):998-1001. PubMed ID: 22356035
[TBL] [Abstract][Full Text] [Related]
9. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.
Lindgren S; Wikman O; Befrits R; Blom H; Eriksson A; Grännö C; Ung KA; Hjortswang H; Lindgren A; Unge P
Scand J Gastroenterol; 2009; 44(7):838-45. PubMed ID: 19330567
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
[TBL] [Abstract][Full Text] [Related]
13. [Pathophysiological-based diagnosis and therapy of iron-deficient anaemia in inflammatory bowel disease].
Stein JM; Hartmann F; Cordes HJ; Dignass AU
Z Gastroenterol; 2009 Feb; 47(2):228-36. PubMed ID: 19197827
[TBL] [Abstract][Full Text] [Related]
14. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
Macdougall IC; Matcham J; Gray SJ;
Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
17. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
18. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment.
Kulnigg S; Teischinger L; Dejaco C; Waldhör T; Gasche C
Am J Gastroenterol; 2009 Jun; 104(6):1460-7. PubMed ID: 19491860
[TBL] [Abstract][Full Text] [Related]
19. The use of darbepoetin in infants with chronic renal impairment.
Durkan AM; Keating LE; Vigneux A; Geary DF
Pediatr Nephrol; 2006 May; 21(5):694-7. PubMed ID: 16565871
[TBL] [Abstract][Full Text] [Related]
20. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]